Considered together with our findings, AT1R antagonists would be beneficial both for controlling hypertension by blocking AT1R-mediated vessel contraction and for preventing end-stage renal disease by suppressing the AT1R-mediated mesangial oxidative stress. This evidence concerns the gene AGTR1 and chronic kidney disease.